FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
31 letters match. Newest first.
-
DrugsHydraMed IV LLC dba HydraMed
FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsEden Health International Inc. dba Eden
FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsTrinity HealthCare Supply, LLC dba altRx
FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.
Low -
DrugsAmie Health, Inc. dba Amie
FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsVivioMD Group LLC dba VivioMD
FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.
Low -
DrugsGlow Medispa, LLC dba Mint Med
FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.
Low -
DrugsNexlife Inc. dba Nexlife
FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.
Low -
DrugsPublic Health Solution LLC dba DrMedHealth
FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMomentum Health 360 dba Momentum Health
FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
Low -
DrugsReady Med
FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.
Low -
DrugsOrderlyMeds LLC dba OrderlyMeds
FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.
Low -
DrugsNova Vascular LLC dba NOVARX
FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.
Low -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsMaximus Health, Inc. dba Maximus
FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.
Low -
DrugsLean Rx, Inc. dba SkinnyRx
SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.
Low -
DrugsKare Solutions, LLC dba Zappy
FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
Low -
DrugsStrut Health, LLC dba Strut
FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.
Low -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsPeaks Curative, LLC dba Peaks
FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.
Low -
DrugsPharmaZee
FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.
Low -
DrugsGood Girl LLC dba GoodGirlRX
FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.
Medium -
DrugsJoin Josie
FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
DrugsLevity Inc. dba Levity
FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.
Low -
DrugsNewSelf Limited dba NewSelf
FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.
Low -
DrugsAlan Health Technologies Inc. dba Alan
FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.
Low -
DrugsDripgym Mobile Parent, LLC dba Amp Health
FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.
Low -
DrugsDeluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics
FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.
Low -
DrugsAspen Aesthetics dba Fifty 410
FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.
Low